INTRODUCTION
Kallikreins are highly specific kininogen-processing serine proteinases found in plasma and in various animal tissues [1] . Tissue kallikreins are species-specific, and very similar amino acid sequences for kallikreins from different animal species have been reported [2] . Tissue kallikreins (EC 3.4.21.35) and plasma kallikreins (EC 3.4.21.34) are distinct enzymes, both in their chemical and in their enzymic properties [3] . The latter release bradykinin from kininogen by the cleavage of a Lys-Arg and an Arg-Ser bond [4] , while the former, with the exception of the rat enzyme [5] , cleave a Met-Lys and an Arg-Ser bond to release Lys-bradykinin [6] . These cleavage specificities have been shown to be determined by secondary enzyme-substrate interactions [7] .
The first evidence for an extended binding site for tissue kallikreins was obtained from the X-ray crystal structure of the aprotinin-(pig tissue kallikrein complex) [8] . Details of the extension of this binding site for cleavage of Arg-Ser and Met-Lys bonds were obtained from studies on the hydrolysis by human tissue kallikrein of oligopeptides having the sequence of human kininogen flanking these susceptible Arg-Ser and MetLys bonds [9] .
Studies by Fiedler et al. [10] , Ketner and Shaw [11] , Prado et al. [12] and Arau! jo-Viel et al. [13] on the specificities of tissue kallikrein subsites S $ -Sh # (nomenclature of Schechter and Berger [14] ) resulted in the development of better substrates for these enzymes, including the chromogenic substrate -Pro-Phe-ArgpNA (where pNA is p-nitroanilide), which is also susceptible to plasma kallikrein [10] , and the internally quenched fluorogenic substrate Abz-Phe-Arg-Ser-Arg-EDDnp [where Abz is o-aminobenzoyl and EDDnp is N- (2,4-dinitrophenyl) ethylenediamine], which discriminates between tissue and plasma kallikreins [15] . In recent work [16] we have reported that
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‡ To whom correspondence should be addressed. substitution of arginine by phenylalanine in these structures leads to substrates specific for the kallidin-releasing tissue kallikreins, i.e. they are resistant to rat tissue and plasma kallikreins, as well as to other arginyl hydrolases. The aim of the present work was to develop inhibitors for kallidin-releasing tissue kallikreins. The interest in these inhibitors derives from evidence implicating the kallikrein\kinin system in a variety of physiological as well as pathological processes [17] . The modifications introduced in the sequences of tissue kallikrein substrates were based on previous [7] and new [16] data on the interactions of the enzyme S $ -Sh $ subsites with specific amino acid residues, which were shown to result in low K m and k cat values and\or a higher specificity for the kallidinreleasing kallikreins.
MATERIALS AND METHODS

Synthesis of peptidyl-pNAs and peptides
Previously described procedures were used for the synthesis, purification and analysis of N α -substituted arginine-and phenylalanine-pNAs [18] and of the intramolecularly quenched fluorogenic peptides having Abz and EDDnp as a donoracceptor pair at the N-and C-termini of the peptides respectively [15] . Peptides with arginine-NH # as the C-terminal residue were synthesized by solid-phase peptide synthesis as described previously [19] . The final deprotected peptides were purified by semi-preparative HPLC using an Econosil C-18 column (10 µm; 22.5 mmi250 mm) and two solvent systems : A, trifluoroacetic acid\water (1 : 1000, v\v) ; B, trifluoroacetic acid\acetonitrile\ water (1 : 900 : 100, by vol.). The column was eluted at a flow rate of 5 ml\min with a 10 (or 30)-50 % (or 60 %) gradient of system B over 30 or 45 min. Analytical HPLC was performed using a C-R7A Shimadzu UV\visible detector and a Shimadzu RF-535 fluorescence detector, coupled to an Ultrasphere C-18 column (5 µm ; 4.6 mmi150 mm) which was eluted with solvent systems A and B at a flow rate of 1.7 ml\min and a 10-80 % gradient of solvent B over 15 min. The HPLC column eluates were monitored by absorbance at 220 nm and by fluorescence emission at 420 nm following excitation at 320 nm. These HPLC conditions were also used for the identification of the products of enzymic hydrolyses and for assays of the resistance of the inhibitors to cleavage by the kallikreins. Amino acid analyses were carried out in a Beckman 6300 amino acid analyser following hydrolysis in 6 M HCl with 5 % phenol at 110 mC for 48 h. [20] . The molar concentrations of the enzyme solutions were determined by active-site titration with 4-nitrophenyl 4-guanidinobenzoate [21] .
Enzymes
Enzyme assays
The hydrolysis of the peptidyl-pNAs at 30 mC in 0.05 M Tris\HCl, pH 9.0, containing 1 mM EDTA was measured photometrically as previously described [22] by determining the amount of pnitroaniline released after the addition of enzyme to 2 ml of reaction buffer. Hydrolysis was carried out for 5-10 min, and initial hydrolytic rates were calculated from the slope of the timedependent absorbance curves extrapolated to zero time.
Hydrolysis of the fluorogenic peptide substrates at 30 mC in 0.02 M Tris\HCl, pH 9.0, containing 1 mM EDTA was monitored by measuring the fluorescence at λ em l 420 nm and λ ex l 320 nm in a Hitachi F-2000 spectrofluorimeter, as previously described [15] .
The concentrations of the peptide substrate solutions were determined from the concentrations of the products of their total hydrolysis by trypsin or chymotrypsin, as previously described [7, 16] . The concentrations of the inhibitor solutions were determined by amino acid analysis.
Inhibition studies
The chromogenic (-Pro-Phe-Phe-pNA) and fluorogenic (AbzPhe-Arg-Ser-Ser-Arg-EDDnp) substrates for human tissue kallikrein (K m values of 10.8 and 0.19 µM respectively at 30 mC and pH 9.0) were used to assay the peptide inhibitors. In the case of the N α -substituted arginine-and phenylalanine-pNAs, the fluorogenic substrate could not be used because of the quenching effect of these compounds on the fluorescence of the hydrolysis products. The type of inhibition was determined from Lineweaver-Burk plots as described by Segel [23] . Four inhibitor concentrations were used with each of three substrate concentrations. The substrate concentration intervals used corresponded to 1-10iK m , and the limit of substrate hydrolysis was 10 %. The K i values were calculated from Dixon plots [24] and\or from the relationships
, as described by Nicklin and Barrett [25] , where o and i are the initial velocity in the absence and presence respectively of the inhibitor.
Progress curve analysis of enzyme inhibition
The kinetics of the inhibition of human tissue kallikrein by BzArg-pNA and Pac-Phe-Ser-Arg-EDDnp (inhibitors A and E-4 respectively ; where Bz is benzoyl and Pac is phenylacetyl) were assessed using the progress curve method described by Bieth [26] . For these inhibition studies the hydrolysis of the fluorescent substrate -Pro-Phe-Phe-MCA (where MCA is 7-amino-4-methylcoumarin) was monitored by measuring the fluorescence at λ em l 380 nm and λ ex 420 nm in an Applied Photophysics stopped-flow instrument operated at 30 mC [27] . The concentrations of -Pro-Phe-Phe-MCA and enzyme were fixed at 7.5 µM (0.1iK m ) and 10 nM respectively, while the inhibitor concentration was varied from 50 nM to a concentration equivalent to the K i for each inhibitor. In each case the progress curves were biphasic, with an initial exponential phase followed by a linear phase, and could be analysed by non-linear regression curve fitting, using the software supplied with the stopped-flow apparatus, to the following equation defining the rate of product (P) formation :
where z is the initial reaction velocity at zero time (t), s is the final steady-state reaction velocity and k is the pseudo-first-order rate constant for the approach to steady state [26] . Generally, the exponential phase lasted between 60 and 90 s, and the progress curves were analysed over 200 s, during which time less than 5 % of the substrate was depleted, as assessed by comparison with the final fluorescence level. Each progress curve analysed was the average of between five and ten traces generated in the stoppedflow instrument. The constant k is related to the association constant k ass and the dissociation constant k diss [26] by the equation :
RESULTS AND DISCUSSION
The tissue kallikrein inhibitors developed in the present work were divided into five series (A, B, C, D and E) according to the model substrate used for their design [Bz-Arg-pNA, -Pro-PhePhe-pNA, Abz-Phe-Arg-Ser-Arg-EDDnp, Abz-Phe-Arg-ArgVal-EDDnp and Abz-Phe-Phe-Ser-Arg-EDDnp respectively]. They were characterized as competitive inhibitors of human tissue kallikrein and shown to be resistant after a 1 h incubation at the conditions used for K i determination ([human tissue kallikrein] l 1 nM ; [I] l 0.1-50 µM; 37 mC, pH 9.0). Increasing the concentrations of the inhibitors and the kallikrein to 150 µM and 43 nM respectively, and the incubation time to 4 h, led to partial hydrolysis of Bz-Arg-pNA, Abz-Arg-pNA, Bz-Arg-NH # and Bz-Arg-OEt (OEt is ethyl ester). All the other compounds in Tables 1 and 2 were shown by HPLC analyses to be resistant to human tissue kallikrein.
Inhibition of kallikreins by N α -substituted Arg-or Phe-pNAs
Analogues of Bz-Arg-pNA (series A)
Bz-Arg-pNA, characterized as a poor substrate for human tissue kallikrein (K m 3.5 mM and k cat 0.085 s −" at 37 mC, pH 9.0), behaved as a competitive inhibitor of this enzyme, as demonstrated by the Lineweaver-Burk plot for the hydrolysis of -ProPhe-Arg-pNA. The K i values calculated from the Dixon plot and from the K i (app) were found to be 1.0 and 0.8 µM respectively. In contrast, Bz-Arg-pNA was shown to be a substrate for human plasma kallikrein (K m 0.13 mM and k cat 15 s −" at 37 mC, pH 8.0). The analogue compound, Bz-Phe-pNA (A-1), possessed similar K i values for both tissue and plasma kallikreins ( Table 1) . The Arg-and Phe-pNAs with Pac as the N-terminal group (A-4 and A-5) had the lowest K i values for human tissue kallikrein in this series, and were neither inhibitors nor substrates of human plasma kallikrein under the conditions described in Table 1 . In contrast, Pac-( pNO # )Phe-pNA (A-6) had similar K i values for both kallikreins, while a lower value for the plasma enzyme was shown for Bz-( pNO # )Phe-anilide (A-9). The K i values in Table 1 also show that Bz-Arg-pNA and Bz-Phe-pNA are better inhibitors of human tissue kallikrein than the corresponding anilides, esters and, particularly, amides. Bz-(pNO # )Phe-anilide (A-9) was a more efficient inhibitor of tissue kallikrein than was Bz-Phe-anilide (A-8), and was also more active against plasma kallikrein, as demonstrated by the 600-fold lower K i value (Table  1) . For the N-terminal side residues (P # position), the order of increasing K i values was phenylacetylated benzoylated oaminobenzoylated residues. The lower K i values for Pac-ArgpNA (A-4) and Pac-Phe-pNA (A-5) in comparison with Bz-Arg-pNA (A) and Bz-Phe-pNA (A-1) respectively suggest that the α-methylene group in the Pac radical elongates the molecule, allowing the benzyl group to reach the S # subsite and thus favouring the inhibitor-enzyme interaction.
Analogues of D-Pro-Phe-Phe-pNA (series B)
The substitution of a Bz group for -proline (compound B-1) in -Pro-Phe-Phe-pNA, a recently described substrate that is specific for kallidin-releasing tissue kallikreins [16] , resulted in a more potent human tissue kallikrein inhibitor (B-1) which also inhibited plasma kallikrein but with a 325-fold higher K i value ( Table 1 ). The preference of subsite S $ for Bz compared with Abz was demonstrated by the higher K i value of Abz-Phe-Phe-pNA (B-2) in comparison with Bz-Phe-Phe-pNA (B-1). Bz-Phe-( pNH # )Phe-pNA (compound B-3) did not behave as an inhibitor of human tissue kallikrein. As expected from the well known specificity of the tissue kallikrein S # subsite for hydrophobic amino acid residues [27] , the substitution of phenylalanine at position P # by glycine resulted in a higher K i value (compound B-4). In agreement with the above observations with compounds Pac-( pNO # )Phe-pNA (A-6) and Bz-(pNO # )Phe-anilide (A-9), the introduction of an NO # group at the para position of phenylalanine, as in Bz-Gly-( pNO # )Phe-pNA (compound B-5), resulted in a significant decrease in the K i values for the inhibition of plasma kallikrein. These data suggest that the charge distribution around the NO # group and\or one of the resonance forms in the nitrophenyl ring induce a very favourable fitting of this radical into the S " subsite, particularly of plasma kallikrein.
Peptide inhibitors of human tissue kallikrein
Analogues of Abz-Phe-Arg-Arg-Val-EDDnp (series C)
This peptide was chosen as one of the model substrates for design of inhibitors because of the favourable interactions of the tissue kallikrein S # subsite with phenylalanine [28] and of the S " and Sh " subsites with arginine [15] . Valine was replaced by proline in peptide C-1 (Table 2) , since it was previously demonstrated that arginyl bonds having proline in the Ph # position are resistant to cleavage by kallidin-releasing tissue kallikreins [15] . Based upon data on the specificity of the tissue kallikreins Sh $ subsite [16] , an The concentrations of Bz-Arg-pNA and Pac-Phe-Arg-Ser-EDDnp were determined by analysing the progress curves generated by stopped-flow mixing of equal volumes of the enzyme with the substrate/inhibitors. In each case the trace was biphasic, and the rate constant (k ) could be determined by non-linear curve fitting to eqn. (1) (see the Materials and methods section). The line through the data points is the best-fit linear regression line for each data set.
arginine was introduced at the C-terminus. These replacements resulted in the inhibitor Abz-Phe-Arg-Arg-Pro-Arg-EDDnp (compound C-2) having the lowest K i value of all the inhibitors developed in this study (Table 2 ). However, this peptide is known to be a good substrate for plasma kallikreins and other arginyl hydrolases [12] . The replacement of arginine by phenylalanine at the P " position of peptide C-2 resulted in peptide C-3, which is a less efficient inhibitor of the kallidin-releasing tissue kallikreins but is resistant to plasma kallikrein. We introduced a Bz instead of an Abz group at the N-terminus of peptides C-3 and C-4, since, as shown in Table 1 , the K i value for Bz-Phe-Phe-pNA (B-1) was 30-fold lower than that for Abz-Phe-Phe-pNA. In addition, in the peptides C-3 to C-7, EDDnp was replaced by NH # , because these peptides could be synthesized by solid-phase methods and this modification did not result in significant variation in the K i values for tissue kallikrein inhibition (see below for compounds D-1 and D-2). In agreement with our data for peptide B-2 (Table 1) , the K i value for the inhibitor C-4 containing (pNH # )Phe as the P " residue was higher than for the analogue that had Phe at this position. The peptide with a Pac group at the P $ position (C-5) did not show any improvement in enzyme inhibition compared with peptide C-3. Further modifications at the P $ position of this peptide, namely εNH # -caproyl Table 2 .
(peptide C-6) and -arginine (peptide C-7), resulted in less efficient inhibitors.
Analogues of Abz-Phe-Arg-Ser-Arg-EDDnp (series D)
This model peptide is the best peptide substrate described so far for human tissue kallikrein (K m 0.04 µM; k cat 1.01 s −" ; k cat \K m 25 250 mM:s −" ) [16] . The replacement of serine by proline at the Ph " position led to the expected resistance of the Arg-Pro bond to hydrolysis by tissue kallikreins and other arginyl hydrolases. This change also resulted in an efficient inhibitor of human tissue kallikrein. The data in Table 2 confirm the preference of the S $ subsite for the Bz group, and also indicate that there were no differences in the interaction of the Sh $ subsite with the amide and EDDnp groups.
Analogues of Abz-Phe-Phe-Ser-Arg-EDDnp (series E)
As previously reported [15] , the substitution of Phe for Arg at the P " position of the peptide Abz-Phe-Arg-Ser-Arg-EDDnp resulted in a substrate that was less efficient with human tissue kallikrein (k cat \K m 3667 mM:s −" ) but specific for kallidin-releasing tissue kallikreins. Substituting the Abz group in this peptide with Bz produced an inhibitor with a K i value of 0.1 µM. For the analogue having ( pNO # )Phe in the P " position (E-3), the K i value was not significantly different from that of peptide E-2. In contrast with above observations with Bz-Arg-pNA and Bz-PhepNA, the presence of Pac at the P # position (peptide E-4) resulted in an inhibitor with a higher K i value.
Progress curve analysis of the inhibition of human tissue kallikrein by Bz-Arg-pNA and Pac-Phe-Ser-Arg-EDDnp
For both inhibitors the pseudo-first-order rate constant (k) for the approach to the steady state was found to increase in a linear manner (Figure 1 ), indicating the occurrence of a single-step mechanism for reversible formation of the enzyme-inhibitor complex [26] . Under these circumstances, the rate constant k is related to the association (k ass ) and dissociation (k diss ) rate constants as described in eqn. (2) .
The values of k ass and k diss were calculated from the data for the hydrolysis of 7.5 µM -Pro-Phe-Phe-MCA, which occurs with a K m of 70.8 µM and a k cat of 12.5 s −" . The K i values for both inhibitors obtained from the ratio k ass \k diss are in good agreement with those obtained from steady-state analyses of the inhibition kinetics, as shown in Table 3 .
None of the peptide inhibitors of human tissue kallikrein in series C, D and E (Table 2) were able to inhibit human plasma kallikrein, even at concentrations 1000-fold higher than those used to determine the K i values for human tissue kallikrein. With the exception of peptides C-1 and C-2, all of the peptides (each at 150 µM) in Table 2 were resistant to degradation by plasma kallikrein (56 nM) during a 4 h incubation at pH 9.0 and 37 mC.
The Arg-Pro bond of the D-series inhibitors was resistant to arginyl hydrolases, but the C-terminal amides NH # and EDDnp were cleaved by trypsin and plasmin.
The most efficient inhibitors of human tissue kallikrein designed in the present work (A-5, B-1, E-1 and E-4) were also assayed for their ability to inhibit pig tissue kallikrein ; the K i values found (0.9, 0.4, 0.5 and 0.7 µM respectively) were similar to those found for human tissue kallikrein (0.8, 0.4, 0.1 and 0.7 µM respectively). In contrast, these peptides were very inefficient inhibitors of rat tissue kallikrein, a bradykinin-releasing enzyme. The K i values for Bz-Phe-Phe-pNA (B-1) and Abz-Phe-Arg-Pro-Arg-EDDnp (D-2) were, respectively, 375-and 70-fold higher for the rat than for the human enzyme. Bz-PhePhe-Arg-Pro-Arg-NH # (C-3), Bz-Phe-Phe-Ser-Arg-EDDnp (E-1) and Pac-Phe-Ser-Arg-EDDnp (E-4) did not behave as inhibitors of rat kallikrein, and the hydrolysis of these peptides could not be detected even after a 4 h incubation with this enzyme.
Okamoto et al. [29] have described PKSI-527 (trans-4-aminomethylcyclohexane carbonylphenylalanine-4-carboxymethylaniline) as a selective inhibitor of plasma kallikrein. We have confirmed this specificity and have demonstrated that PKSI-527 is also an inhibitor of rat tissue kallikrein with a K i value of 1.1 µM. Szelke et al. [30] described a series of synthetic inhibitors of tissue and plasma kallikreins. The most potent and selective inhibitor for tissue kallikrein was -Pro-Phe-,-Arg-CH # -(hexyl) # , which had a K i of 0.33 µM, 58-fold lower than the K i for human plasma kallikrein.
In conclusion, the tissue kallikrein inhibitors described in the present paper belong to the first group of selective inhibitors of kallidin-releasing kallikreins to be reported, without detectable activity as plasma kallikrein substrates or inhibitors. The effects of these inhibitors have been screened in two biological systems, namely inhibition of the microvascular permeability induced by pig tissue kallikrein in rabbit skin in i o, and inhibition of the relaxation of rabbit corpus cavernosum strips induced by this same enzyme. We chose to use Pac-Phe-Ser-Arg-EDDnp (E-4) for systematic biological assays, and this inhibitor was found to be the most active compound in both assays [31] .
